{"meta":{"totalResults":9,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"fluorouracil-epirubicin-cyclophosphamide regimen"},{"type":"Synonym","name":"FEC"},{"type":"Synonym","name":"CEF"},{"type":"Synonym","name":"FEC 100"},{"type":"Synonym","name":"CTX/EPI/5-FU"},{"type":"Synonym","name":"CEF regimen"}],"definition":{"html":"A regimen consisting of fluorouracil, epirubicin and cyclophosphamide used in the adjuvant setting and also for the treatment of recurrent and metastatic breast cancer.","text":"A regimen consisting of fluorouracil, epirubicin and cyclophosphamide used in the adjuvant setting and also for the treatment of recurrent and metastatic breast cancer."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/FEC","text":"FEC"},"nciConceptId":"C9595","nciConceptName":"FEC Regimen","termId":657171,"name":"FEC Regimen","firstLetter":"f","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"fec-regimen"},{"aliases":[{"type":"Abbreviation","name":"5-FU injection"},{"type":"Synonym","name":"5-Fluracil"},{"type":"LexicalVariant","name":"5FU injection"},{"type":"ObsoleteName","name":"Adrucil"},{"type":"Abbreviation","name":"FU"},{"type":"Synonym","name":"Fluracil"},{"type":"ForeignBrandName","name":"Fluril"},{"type":"ChemicalStructureName","name":"2,4-dioxo-5-fluoropyrimidine"},{"type":"ChemicalStructureName","name":"5-fluoro-2,4(1H,3H)-pyrimidinedione"},{"type":"ForeignBrandName","name":"AccuSite"},{"type":"Synonym","name":"fluouracil"},{"type":"ForeignBrandName","name":"Flurablastin"},{"type":"ForeignBrandName","name":"Fluracedyl"},{"type":"ForeignBrandName","name":"Fluroblastin"},{"type":"ForeignBrandName","name":"Ribofluor"},{"type":"CodeName","name":"Ro-2-9757"},{"type":"NSCNumber","name":"19893"},{"type":"CASRegistryName","name":"51-21-8"},{"type":"Synonym","name":"5 fluorouracil"},{"type":"Synonym","name":"5 fluorouracilum"},{"type":"Abbreviation","name":"5 FU"},{"type":"Synonym","name":"5-fluorouracil"},{"type":"Abbreviation","name":"5-FU"},{"type":"Abbreviation","name":"5FU"},{"type":"USBrandName","name":"Carac"},{"type":"Synonym","name":"Fluoro Uracil"}],"definition":{"html":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","text":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/fluorouracil","text":"Fluorouracil Injection"},"nciConceptId":"C505","nciConceptName":"Fluorouracil","termId":43130,"name":"fluorouracil","firstLetter":"f","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"fluorouracil"},{"aliases":[{"type":"ForeignBrandName","name":"Sinofuan"}],"definition":{"html":"An implant containing a sustained release particle of fluorouracil, an antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine, with antineoplastic activity. Upon implantation and subsequent release, fluorouracil is converted into the active metabolite 5-fluoroxyuridine monophosphate that competes with the pyrimidine uracil during RNA synthesis while another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate, inhibits thymidylate synthase and thus DNA synthesis.","text":"An implant containing a sustained release particle of fluorouracil, an antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine, with antineoplastic activity. Upon implantation and subsequent release, fluorouracil is converted into the active metabolite 5-fluoroxyuridine monophosphate that competes with the pyrimidine uracil during RNA synthesis while another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate, inhibits thymidylate synthase and thus DNA synthesis."},"drugInfoSummaryLink":null,"nciConceptId":"C90544","nciConceptName":"Fluorouracil Implant","termId":665364,"name":"fluorouracil implant","firstLetter":"f","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"fluorouracil-implant"},{"aliases":[{"type":"Abbreviation","name":"5-FU-e TI"},{"type":"Synonym","name":"5-FU/epi gel"},{"type":"Synonym","name":"5-fluorouracil/epi"},{"type":"Synonym","name":"fluorouracil-epinephrine therapeutic implant"},{"type":"Synonym","name":"fluorouracil/epi"}],"definition":{"html":"An injectable collagen matrix gel containing the antimetabolite fluorouracil and the sympathicomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, fluorouracil is converted into the active metabolite 5-fluoroxyuridine monophosphate that competes with uracil during RNA synthesis while another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate, inhibits thymidylate synthase and, so, DNA synthesis. Epinephrine, a potent vasoconstrictor, is added to the gel to enhance penetration of fluorouracil into tumor tissue and reduce dispersion to  surrounding tissues, thus enhancing the local concentration of fluorouracil. Compared to systemic administration, the  intratumoral injection of fluorouracil combined with epinephrine may increase  fluorouracil's chemotherapeutic efficacy while minimizing systemic toxicity.","text":"An injectable collagen matrix gel containing the antimetabolite fluorouracil and the sympathicomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, fluorouracil is converted into the active metabolite 5-fluoroxyuridine monophosphate that competes with uracil during RNA synthesis while another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate, inhibits thymidylate synthase and, so, DNA synthesis. Epinephrine, a potent vasoconstrictor, is added to the gel to enhance penetration of fluorouracil into tumor tissue and reduce dispersion to  surrounding tissues, thus enhancing the local concentration of fluorouracil. Compared to systemic administration, the  intratumoral injection of fluorouracil combined with epinephrine may increase  fluorouracil's chemotherapeutic efficacy while minimizing systemic toxicity."},"drugInfoSummaryLink":null,"nciConceptId":"C17877","nciConceptName":"Fluorouracil-E Therapeutic Implant","termId":41859,"name":"fluorouracil-e therapeutic implant","firstLetter":"f","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"fluorouracil-e-therapeutic-implant"},{"aliases":[{"type":"Synonym","name":"FOLinic acid-fluorouracil-IRInotecan regimen"},{"type":"Abbreviation","name":"FOLFIRI"},{"type":"Synonym","name":"fluorouracil-folinic acid-irinotecan"},{"type":"Synonym","name":"fluorouracil/folinic acid/irinotecan"},{"type":"Synonym","name":"fluorouracil/leucovorin/irinotecan"},{"type":"Synonym","name":"folinic acid/fluorouracil/irinotecan regimen"}],"definition":{"html":"A regimen consisting of leucovorin calcium (calcium folinate), 5-fluorouracil, and irinotecan that can be used in the treatment of appendiceal, small bowel, pancreatic and occult primary adenocarcinoma; colorectal, esophageal and esophagogastric junction, gastric, and hepatobiliary cancers; well-differentiated grade 3 neuroendocrine tumors (NETs), and extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm.","text":"A regimen consisting of leucovorin calcium (calcium folinate), 5-fluorouracil, and irinotecan that can be used in the treatment of appendiceal, small bowel, pancreatic and occult primary adenocarcinoma; colorectal, esophageal and esophagogastric junction, gastric, and hepatobiliary cancers; well-differentiated grade 3 neuroendocrine tumors (NETs), and extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/FOLFIRI","text":"FOLFIRI"},"nciConceptId":"C63593","nciConceptName":"FOLFIRI Regimen","termId":41990,"name":"FOLFIRI regimen","firstLetter":"f","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"folfiri-regimen"},{"aliases":[{"type":"Synonym","name":"fluorouracil-leucovorin-irinotecan-oxaliplatin regimen"},{"type":"Synonym","name":"fluorouracil with irinotecan hydrochloride, leucovorin calcium and oxaliplatin"},{"type":"Synonym","name":"FOLFIRINOX protocol"},{"type":"Synonym","name":"fluorouracil/irinotecan/leucovorin calcium/oxaliplatin"},{"type":"Synonym","name":"folinic acid/fluorouracil/irinotecan/oxaliplatin"}],"definition":{"html":"A regimen consisting of fluorouracil, irinotecan, leucovorin and oxaliplatin that can be used for the treatment of pancreatic and colorectal cancers; occult primary, appendiceal and small bowel adenocarcinomas; well-differentiated grade 3 neuroendocrine tumors (NETs), and extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm.","text":"A regimen consisting of fluorouracil, irinotecan, leucovorin and oxaliplatin that can be used for the treatment of pancreatic and colorectal cancers; occult primary, appendiceal and small bowel adenocarcinomas; well-differentiated grade 3 neuroendocrine tumors (NETs), and extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/FOLFIRINOX","text":"FOLFIRINOX"},"nciConceptId":"C11764","nciConceptName":"Folfirinox Regimen","termId":710968,"name":"Folfirinox regimen","firstLetter":"f","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"folfirinox-regimen"},{"aliases":[{"type":"Synonym","name":"FOLinic acid-Fluororuracil-OXaliplatin regimen"},{"type":"Abbreviation","name":"CF/5-FU/L-OHP"},{"type":"Synonym","name":"fluorouracil/leucovorin calcium/oxaliplatin"}],"definition":{"html":"One of several  chemotherapy regimens that include leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin and which may be used in the treatment of advanced-stage and metastatic colorectal cancer. FOLFOX regimens differ in agent dosing and administration schedule and include FOLFOX 4, FOLFOX 6, modified FOLFOX 6 (mFOLFOX 6) and FOLFOX 7.","text":"One of several  chemotherapy regimens that include leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin and which may be used in the treatment of advanced-stage and metastatic colorectal cancer. FOLFOX regimens differ in agent dosing and administration schedule and include FOLFOX 4, FOLFOX 6, modified FOLFOX 6 (mFOLFOX 6) and FOLFOX 7."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/FOLFOX","text":"FOLFOX"},"nciConceptId":"C11197","nciConceptName":"FOLFOX Regimen","termId":42512,"name":"FOLFOX regimen","firstLetter":"f","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"folfox-regimen"},{"aliases":[{"type":"Synonym","name":"fluorouracil-leucovorin regimen"},{"type":"Synonym","name":"de Gramont regimen"},{"type":"Synonym","name":"5FU/LV"}],"definition":{"html":"A regimen consisting of fluorouracil and leucovorin, used in both the adjuvant and metastatic disease setting, for the treatment of colorectal cancer. This regimen is also combined with radiation for the treatment of gastric and esophageal cancer.","text":"A regimen consisting of fluorouracil and leucovorin, used in both the adjuvant and metastatic disease setting, for the treatment of colorectal cancer. This regimen is also combined with radiation for the treatment of gastric and esophageal cancer."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/FU-LV","text":"FU-LV"},"nciConceptId":"C63388","nciConceptName":"FU-LV Regimen","termId":657271,"name":"FU-LV regimen","firstLetter":"f","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"fu-lv-regimen"},{"aliases":[{"type":"Synonym","name":"oxaliplatin-folinic acid-fluorouracil regimen"},{"type":"Synonym","name":"fluorouracil/leucovorin/oxaliplatin regimen"}],"definition":{"html":"A chemotherapy regimen that includes leucovorin, 5-fluorouracil and oxaliplatin, which may be used in the treatment of pancreatic cancer.","text":"A chemotherapy regimen that includes leucovorin, 5-fluorouracil and oxaliplatin, which may be used in the treatment of pancreatic cancer."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/OFF","text":"OFF"},"nciConceptId":"C114101","nciConceptName":"OFF Regimen","termId":758533,"name":"OFF regimen","firstLetter":"o","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"off-regimen"}],"links":null}